← All candidates
21 insider buys in the last year — $1.06M in all.
46 filings on record.
BCDABioCardia, Inc.
NasdaqCM · Healthcare · $18.92M
$1.25
+1.63% today
21 insider buys in the last year — $1.06M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 21 buys◆ 25 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 5×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what BCDA ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$18.92M
Float
12.3M
81% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Stertzer Simon H
Bought $498.0K on Sep 19 — 398,400 sh @ $1.25, held indirect, 67% of their stake.
0 of 1 position beat the S&P
Director
Blank Andrew Scott
Bought $360.0K on Sep 19 — 288,000 sh @ $1.25, held indirect, 45% of their stake.
0 of 1 position beat the S&P
President and CEO
Altman Peter
Bought $60.0K on Sep 19 — 48,000 sh @ $1.25, held direct, 22% of their stake.
1 of 12 positions beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
37 more transactions on Pro →Context
Wall St
$15.50 avg target
+1140.0% vs today · 2 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.21 act−$0.04
Q4 '25−$0.06 act+$0.14
Q3 '25−$0.24 act+$0.01
Q2 '25−$0.40 act+$0.10
Coverage
The file stays open
46 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice